Arena shares slip after Merck dumps pact

Shares of Arena Pharmaceuticals slipped six percent after the developer announced that Merck is dropping out of their collaboration on a new atherosclerosis therapy. Merck decided to opt out after MK-1903 flunked a mid-stage trial.  Story